June – foundation of Cambridge Oncometrix Limited, incorporated in England and Wales, Company No. 8101482. Company’s goal is development and commercialisation of simple reliable tests for prostate cancer diagnostics.
Invention of novel prostate cancer biomarkers was inspired by the cross-pollination of ideas from co-founders’ work in cancer research and ground-breaking works of Professor Vladimir Zaichick.
September - foundation of the subsidiary Oncometrix LLC, St. Petersburg, Russia. Company’s goal – facilitate clinical studies and medical research.
October - after rigorous selection by international expert panel Oncometrix LLC obtains participant status in SKOLKOVO Foundation, Moscow, Russia.
April - established collaboration with Hospital Bassini, Cinisello Balsamo, Milan, Italy.
May - ONCOMETRIX LLC obtains prise from SKOLKOVO Foundation as a top 20 Finalist in StartUp Village competition, Skolkovo, Russia.
August - established collaboration with Alexandrovskij Hospital, St. Petersburg, Russia.
May - a GB patent application on prostate cancer biomarkers submitted to the UK Intellectual Property Office.
February - obtained approval from the Independent Interdisciplinary Ethical Committee, Moscow, for conducting of the clinical study “PROSTATEST” in Russia.
April - finalist in business idea competition at the Innovation Forum, Cambridge.